T
Tejaswini Dhawale
Researcher at Harvard University
Publications - 17
Citations - 378
Tejaswini Dhawale is an academic researcher from Harvard University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 6, co-authored 13 publications receiving 225 citations. Previous affiliations of Tejaswini Dhawale include University of Washington.
Papers
More filters
Journal ArticleDOI
The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells.
Alexandre V. Hirayama,Jordan Gauthier,Kevin A. Hay,Kevin A. Hay,Jenna M. Voutsinas,Qian Wu,Ted Gooley,Daniel Li,Sindhu Cherian,Xueyan Chen,Barbara S. Pender,Reed M. Hawkins,Aesha Vakil,Rachel N. Steinmetz,Utkarsh Acharya,Utkarsh Acharya,Ryan D. Cassaday,Ryan D. Cassaday,Aude G. Chapuis,Aude G. Chapuis,Tejaswini Dhawale,Paul C. Hendrie,Hans-Peter Kiem,Hans-Peter Kiem,Ryan C. Lynch,Ryan C. Lynch,J L Ramos,J L Ramos,Mazyar Shadman,Mazyar Shadman,Brian G. Till,Brian G. Till,Stanley R. Riddell,Stanley R. Riddell,David G. Maloney,David G. Maloney,Cameron J. Turtle,Cameron J. Turtle +37 more
TL;DR: Analysis of clinical and treatment characteristics, serum biomarkers, and CAR T-cell manufacturing and pharmacokinetic data showed that a lower pre-lymphodepletion serum lactate dehydrogenase (LDH) level and a favorable cytokine profile, defined as serum day 0 monocyte chemoattractant protein-1 (MCP-1) and peak interleukin-7 (IL-7) concentrations above the median, were associated with better PFS.
Journal ArticleDOI
Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy
Utkarsh Acharya,Tejaswini Dhawale,Seongseok Yun,Caron A. Jacobson,Julio C. Chavez,Jorge Ramos,Jacob S. Appelbaum,David G. Maloney +7 more
TL;DR: This manuscript provides an in-depth overview of the pathogenesis, clinical characteristics, current toxicity management strategies, and future perspectives pertaining to CRS and neurotoxicity.
Journal ArticleDOI
Comparison of Efficacy and Toxicity of CD19-Specific Chimeric Antigen Receptor T-Cells Alone or in Combination with Ibrutinib for Relapsed and/or Refractory CLL
Jordan Gauthier,Alexandre V. Hirayama,Kevin A. Hay,Kevin A. Hay,Daniel Li,James Lymp,Alyssa Sheih,Janaki Purushe,Barbara S. Pender,Reed M. Hawkins,Aesha Vakil,Tinh-Doan Phi,Rachel N. Steinmetz,Aude G. Chapuis,Aude G. Chapuis,Brian G. Till,Brian G. Till,Tejaswini Dhawale,Paul C. Hendrie,Hans-Peter Kiem,Hans-Peter Kiem,Jorge Ramos,Jorge Ramos,Mazyar Shadman,Mazyar Shadman,Ryan D. Cassaday,Ryan D. Cassaday,Utkarsh Acharya,Utkarsh Acharya,Utkarsh Acharya,Stanley R. Riddell,Stanley R. Riddell,David G. Maloney,David G. Maloney,Cameron J. Turtle,Cameron J. Turtle +35 more
TL;DR: Durable responses to CD19-specific chimeric antigen receptor-modified T-cell therapy (JCAR014) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) patients after prior failure of ibrutinib are reported.
Journal ArticleDOI
Uncertainty of Physicians and Patients in Medical Decision Making.
TL;DR: Various aspects of uncertainty and their relevance in the process of medical decision making are examined as briefly illustrated by 2 clinical scenarios of hematologic malignancies.
Journal ArticleDOI
Autologous and Allogeneic Hematopoietic Cell Transplantation in Peripheral T/NK-cell Lymphomas: A Histology-Specific Review
TL;DR: The best available data suggest that certain subtypes of PT/NKCL may benefit more from the application of HSCT than other subtypes and that this benefit results from their unique clinical characteristics and underlying biology.